Cardeas Pharma, a US-based drugs maker developing antibiotics, has raised $34m in its series B round from a consortium including Denmark-based peer Novo.

Venture capital firms HIG BioVentures, which led the B roundAvalon Ventures, Delphi Ventures and Devon Park Bioventures and Washington Research Foundation’s WRF Capital joined HIG in the consortium.

In June last year, Cardeas raised $8.5m in it’s A round, led by Novo.

At that time, Peter Moldt, partner of Novo, said: “This [Cardeas’] exemplary management team has the experience and commitment to build a leading company in respiratory infection.”

Cardeas Pharma, a US-based drugs maker developing antibiotics, has raised $34m in its series B round from a consortium including Denmark-based peer Novo.

Venture capital firms HIG BioVentures, which led the B roundAvalon Ventures, Delphi Ventures and Devon Park Bioventures and Washington Research Foundation’s WRF Capital joined HIG in the consortium.

In June last year, Cardeas raised $8.5m in it’s A round, led by Novo.

At that time, Peter Moldt, partner of Novo, said: “This [Cardeas’] exemplary management team has the experience and commitment to build a leading company in respiratory infection.”